Lucid Diagnostics

We’re excited to join the International Association of Fire Fighters (IAFF) Affiliate Leadership Training Summit (ALTS) in New Orleans this week. Did you know esophageal cancer is the 2nd most lethal cancer—but it’s also preventable with early detection? 🛡️🔥 Over 5,000 firefighters have already been tested with EsoGuard to help catch disease early. Connect with our team to learn more about esophageal cancer prevention and how EsoGuard is making a difference. See you in NOLA! #IAFF #ALTS2025

"Early detection and preventative screening are paramount in ensuring the health and safety of everyone, but especially firefighters... I strongly encourage all firefighters to take advantage of the #CheckYourFoodTube esophageal precancer screening events, as I did." said Sam Dillon, Boston Firefighters Local 718 IAFF President #FirefighterCancerAwarenessMonth

January is #FirefighterCancerAwarenessMonth 🔥 Cancer is the leading cause of line-of-duty deaths for #firefighters. Research shows firefighters have a 62% higher risk of developing esophageal cancer compared to the general population. Early detection matters. EsoGuard is a quick, non-invasive test that detects esophageal precancer—no sedation needed. It helps catch disease before it becomes cancer. Learn how to make EsoGuard available for your team: https://lnkd.in/gJn_phrX #CheckYourFoodTube

Wishing you a season filled with joy, laughter, and good health! Happy Holidays!

"Integrating EsoGuard into our services perfectly complements our mission to protect first responders' health," said Dr. Marci Vitale. "This partnership enables us to offer cutting-edge precancer screening to the brave individuals who put their lives on the line daily. At VITALExam, we're passionate about early detection and empowering first responders to prioritize their health. By introducing EsoGuard testing into our annual wellness program for Tuscaloosa Fire Rescue, we are making these exams more comprehensive and impactful, furthering our shared mission of saving lives through early detection." See the story from WRBC News here: https://lnkd.in/g3mP8yYC Read more about Lucid Diagnostics partnership with VITALExam here: https://lnkd.in/gwWB429Q

Innovative Pill-Sized Diagnostic Could Revolutionize Esophageal Cancer Prevention Esophageal cancer remains one of the deadliest cancers, yet early detection efforts have lagged behind other major cancers like breast, lung, and colon cancer. Lucid Diagnostics is working to address this gap with an innovative, non-invasive diagnostic tool designed to detect esophageal precancer in patients at risk, such as those suffering from chronic gastroesophageal reflux disease (GERD). As CEO Lishan Aklog, MD states, "The key to preventing 16,000 cancer deaths annually is not detecting it at an early stage but identifying it at the precancer stage." Lucid Diagnostics’s EsoGuard test, cleared by the FDA in 2019, offers a simple and quick alternative to traditional endoscopies. The pill-sized device, attached to a thin catheter, collects cells from the esophagus when swallowed and analyzes them for genetic markers associated with precancer and cancer. Unlike endoscopy, which is invasive and often requires anesthesia, EsoGuard provides a convenient, office-based solution. The process takes just minutes and could potentially reduce the barriers that prevent millions from undergoing screening, helping to detect precancer before it progresses into deadly cancer. Lucid Diagnostics is addressing an unmet need in healthcare, with over 30 million patients annually at risk but not being tested. "The missing link in all of this — so that we could actually prevent these tragic deaths — was a simple, effective, outpatient office-based test," says Aklog. With the promise of broader insurance coverage, including Medicare, this innovation could significantly impact the early detection of esophageal cancer and ultimately save lives. #EsophagealCancer #HealthcareInnovation #CancerPrevention #DiagnosticTechnology #MedTech #EarlyDetection #Gastroenterology #LucidDiagnostics #NonInvasiveTesting #PrecisionMedicine #AIInHealthcare #PatientCare

"EsoGuard enables physicians to effectively triage patients at increased risk for esophageal precancer to confirmatory upper endoscopy. Once again, physicians consistently utilized our non-invasive EsoGuard test to appropriately refer patients to endoscopy, allowing the vast majority of patients to avoid this more expensive and invasive procedure. Patients, in turn, showed an exceptionally high level of compliance with their physician's referral to EGD. This patient compliance data and the study's full provider impact data supplements our strong evidence base of clinical validity, clinical utility and analytical validity data supporting our ongoing discussions with payors and other key stakeholders." said Victoria T. Lee M.D., Lucid's Chief Medical Officer. Read more here: https://lnkd.in/gkYx73JT

Esophageal cancer is a growing healthcare concern with a steady increase in the number of cases in the last four decades, but it doesn’t have to be this way. Dr. Lishan Aklog, MD, joins Daniel Levine on The Bio Report to discuss how the #EsoGuard test detects precancerous conditions early—making prevention possible. Listen here: https://lnkd.in/gYSad9WH

#GERDawarenessWeek is over, but it’s never too late to take charge of your health. Acid indigestion, acid reflux, heartburn... these are all terms commonly associated with GERD or Gastroesophageal reflux disease. Chronic GERD can lead to esophageal disease or even cancer. Don't ignore your symptoms, ask your doctor about the EsoGuard test. Thank you to William Thomas for sharing your insights this week!

Thanks to American Foregut Society President, Dr. Dan Lister, MD FACS FAFS for partnering to generate awareness this #GERDawarenessWeek